NVAX Jan 2025 1.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 09:52AM EDT
| Previous close | 0.0700 |
| Open | 0.0700 |
| Bid | 0.0000 |
| Ask | 0.0300 |
| Strike | 1.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0700 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 101 |
GuruFocus.comInsider Sale: Director James Young Sells Shares of Novavax Inc (NVAX)
On June 18, 2024, James Young, Director at Novavax Inc (NASDAQ:NVAX), executed a sale of 7,500 shares of the company. Following this transaction, the insider now owns 69,260 shares of Novavax Inc. Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
Investor's Business DailyThe FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
ZacksNovavax (NVAX) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
© 2024 Yahoo. All rights reserved.